Janux Therapeutics
JANX
121 hedge funds and large institutions have $1.59B invested in Janux Therapeutics in 2024 Q1 according to their latest regulatory filings, with 63 funds opening new positions, 24 increasing their positions, 29 reducing their positions, and 6 closing their positions.
950% more first-time investments, than exits
New positions opened: 63 | Existing positions closed: 6
342% more capital invested
Capital invested by funds: $360M → $1.59B (+$1.23B)
89% more funds holding
Funds holding: 64 → 121 (+57)
9.24% more ownership
Funds ownership: 72.71% → 81.95% (+9.2%)
17% less repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 29
43% less call options, than puts
Call options by funds: $3.76M | Put options by funds: $6.66M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$67M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$30.9M |
| 3 |
RI
RTW Investments
New York
|
+$21.8M |
| 4 |
O
OrbiMed
New York
|
+$20.9M |
| 5 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$36.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$16.8M |
| 3 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$3.92M |
| 4 |
BlackRock
New York
|
-$1.48M |
| 5 |
Millennium Management
New York
|
-$1.44M |
JANX Hedge Fund Activity: Q1 2024 in Review
121 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Janux Therapeutics (JANX) for Q1 2024, worth a combined $1.59B — up 342% from $360M a quarter earlier.
Buyers outnumbered sellers: 63 funds opened new JANX positions and 6 closed out — a net gain of 57 holders — while 24 added to existing stakes and 29 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $67M. The largest seller was BVF Inc, cutting an estimated $36.2M.
- 121 institutional investors held Janux Therapeutics (JANX) as of Q1 2024, up from 64 in Q4 2023.
- Funds reported $1.59B of Janux Therapeutics stock for Q1 2024, up 342% quarter-over-quarter.
- 63 funds opened new Janux Therapeutics positions in Q1 2024 and 6 closed out, a net change of +57 holders.
- The largest Janux Therapeutics buyer in Q1 2024 was Fidelity Investments, an estimated $67M added.
- The largest Janux Therapeutics seller in Q1 2024 was BVF Inc, an estimated $36.2M sold.
Based on aggregated 13F filings for Q1 2024.